Ceapro Inc V.CZO

Shareholder value???

[fossi_2002]

When Gilles says in the annual report that shareholder value is at the top of his agenda, that is now demonstrably not the truth.

[prophetoffactz]

CZO's stock was $.23 the day before the merger. $.23 is $18 million market cap. Given it is a merger of equals with each group of shareholders controlling 50% of the new company that is equivalent to $36 million market cap for the new company.  AEZS had US$38.8 million cash at the end of the last reporting period and according to Gilles CZO had $10 million in cash at the

[Tencents]

In addition to above we should take into consideration aezs management comments in its  financial statements which states aezs expects to make significant losses for the foreseeable future  this probably meabb nes  the cash on hand will be eaten up by end 2025 and tax losses will not be used in the short to medium term 

[prophetoffactz]

Here's what AEZS's 6-K filing says: "We also believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements beyond the next 12 months and through 2025."  AEZS's existing US$38.8 million cash was expected to last through 2025. That likely doesn't take into account potential licensing payments

[prophetoffactz]

If the merger was cancelled the parties could have informed us by now. We've received nothing. A delay in the deal could bring new developments as AEZS's diagnostic clinical trial was to be fully enrolled by the end of 2023. Results from the trial could be near and this could support a licensing deal. CZO's avenanthramide clinical trial could also be nearing completion of the single